You just read:

Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera

News provided by

Protagonist Therapeutics, Inc.

Oct 30, 2019, 16:49 ET